Navigation Links
Arthritic Drug Approved For Use In Children With Crohn’s Diseas

The Food and Drug Administration in the U.S. have given an approval for the drug Remicade for use in children with active Crohn's disease (CD), which is a chronic// and debilitating condition.

Crohn's disease is an inflammation of the gastrointestinal tract that causes diarrhea, fever, abdominal pain, weight loss and, in some times, delayed development and stunted growth. Though it can involve any area of the gastrointestinal tract from the mouth to the anus, it commonly affects the small intestine.

Remicade has already been approved for treating rheumatoid arthritis and other conditions but now the drug will carry an additional warning about the small risk of an often-fatal lymphoma. It has been found that Remicade and other TNF blockers, may increase the risk of lymphoma or other cancers, and is not recommended for people with heart failure. There are also reports on the drug as it could cause serious infections, including tuberculosis (TB), sepsis and pneumonia, liver injury, and blood disorders.

According to drug company Johnson & Johnson the drug is the first and only biologic therapy that has been approved for the treatment of pediatric Crohn's disease. The officials said that the drug helps in reducing the signs and symptoms of the disease and helps to maintain remission in children suffering from moderate or severe form of Crohn’s disease, and those who have not responded to regular treatment.

The approval was passed after a data from a clinical trial of 112 patients aged 6 to 17 years, found that the children with moderate to severe active Crohn's disease after 10 weeks of therapy with Remicade responded well and more than half were in remission at the end of one year.

Approximately 100,000 children under the age of 17 suffer from inflammatory bowel diseases (IBD), which include CD and ulcerative colitis (UC). Remicade, known generically as infliximab, belongs to a class of drugs that suppress tumo r necrosis factor-alpha, a protein involved in inflammation.

Related medicine news :

1. Do Arthritics Perceive the Importance of Exercise in the Management of Disease?
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
10. Pfizer’s Eraxis Approved By The FD
11. Inhalers for Kids Was Approved By the FDA
Post Your Comments:

(Date:10/12/2015)... ... ... A new invention has just been added to the growing list of consumer ... a conventional nasal aspirator with child safety in mind., He developed a prototype of ... passages more safely and effectively than with standard aspirators. As such, it is ideal ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... Santa Clara dentist , Dr. Alan ... the information provided by the ADHA white paper announcement. , “I want each one of ... have the best possible smile,” states Santa Clara dental implants dentist , Dr. Frame. ...
(Date:10/12/2015)... ... ... fans who are interested in having an opportunity to go to the 2016 Super Bowl ... to Smile for a Lifetime (S4L) Foundation and gift a smile to a child in ... Super Bowl! , Donors contributing $20.00 or more between now and November 30th, 2015 will ...
(Date:10/12/2015)... ... October 12, 2015 , ... For the fourth consecutive year PureFormulas ... distinction with its first Platinum Award. , The Bizrate Circle of Excellence Platinum ... a score of at least 9.0 or above out of 10.0 in all seven ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... has secured a new corporate headquarters, located at 485 Madison Avenue, New York, ... workflow and increased emphasis on cloud-based technology. , “Care to Care is a ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... WARSAW, Ind. , Oct. 12, 2015 ... announced its third quarter 2015 sales and earnings conference ... Thursday, October 29, 2015, at 8 a.m. Eastern Time.  ... made available at 7:30 a.m. Eastern Time the morning ... will be archived for replay following the conference call. ...
(Date:10/12/2015)... , Oct. 12, 2015  Jane ... Chief Scientific Officer of Asterias Biotherapeutics, Inc. ... in the emerging field of regenerative medicine, ... sponsored in part by Asterias Biotherapeutics, featuring ... will discuss the progress to date for ...
(Date:10/12/2015)... YORK , Oct. 12, 2015 This study ... assessments and company profiles. In the two past decades, the ... expansions of the manufacturing capabilities and rising consumer consumptions in ... society and economy. China ... consumer products. Far outpacing other economies in the world, ...
Breaking Medicine Technology: